Moleculin Biotech announced the pricing of a public offering of an aggregate of 2,466,368 shares of its common stock, Series A warrants to purchase up to 2,466,368 shares of common stock and Series B warrants to purchase up to 2,466,368 shares of common stock, at a combined public offering price of $2.23 per share and accompanying warrants. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Moleculin Biotech reports Q2 EPS ($1.70) vs. ($3.02) last year
- Moleculin Biotech (MBRX) Q2 Earnings Cheat Sheet
- Moleculin Biotech Advances Phase 3 Trial for AML Treatment
- Moleculin Biotech Advances to Phase 3 AML Trial